A207940 Stock Overview
Engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A207940 from our risk checks.
Samsung Biologics Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩939,000.00 |
| 52 Week High | ₩1,113,000.00 |
| 52 Week Low | ₩698,000.00 |
| Beta | 0.32 |
| 11 Month Change | -11.33% |
| 3 Month Change | -1.88% |
| 1 Year Change | 30.24% |
| 33 Year Change | 10.86% |
| 5 Year Change | 135.34% |
| Change since IPO | 552.08% |
Recent News & Updates
Samsung Biologics Co.,Ltd. (KRX:207940) Investors Are Less Pessimistic Than Expected
Nov 11
These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well
Sep 09Samsung Biologics Co.,Ltd.'s (KRX:207940) 26% Share Price Surge Not Quite Adding Up
Jul 29Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?
May 27Recent updates
Samsung Biologics Co.,Ltd. (KRX:207940) Investors Are Less Pessimistic Than Expected
Nov 11These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well
Sep 09Samsung Biologics Co.,Ltd.'s (KRX:207940) 26% Share Price Surge Not Quite Adding Up
Jul 29Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?
May 27What Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Is Not Telling You
Apr 14With EPS Growth And More, Samsung BiologicsLtd (KRX:207940) Is Interesting
Mar 01These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well
Jan 18
What Kind Of Shareholders Own Samsung Biologics Co.,Ltd. (KRX:207940)?
Dec 28How Much Is Samsung Biologics Co.,Ltd. (KRX:207940) CEO Getting Paid?
Dec 08Did You Miss Samsung BiologicsLtd's (KRX:207940) Impressive 112% Share Price Gain?
Nov 18Shareholder Returns
| A207940 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | -1.9% | -2.3% | 2.3% |
| 1Y | 30.2% | 34.0% | -3.8% |
Return vs Industry: A207940 underperformed the KR Life Sciences industry which returned 34% over the past year.
Return vs Market: A207940 exceeded the KR Market which returned -3.8% over the past year.
Price Volatility
| A207940 volatility | |
|---|---|
| A207940 Average Weekly Movement | 5.1% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.4% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A207940 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A207940's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 4,523 | John Chongbo Rim | samsungbiologics.com |
Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization.
Samsung Biologics Co.,Ltd. Fundamentals Summary
| A207940 fundamental statistics | |
|---|---|
| Market cap | ₩66.76t |
| Earnings (TTM) | ₩1.03t |
| Revenue (TTM) | ₩4.21t |
65.0x
P/E Ratio15.9x
P/S RatioIs A207940 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A207940 income statement (TTM) | |
|---|---|
| Revenue | ₩4.21t |
| Cost of Revenue | ₩2.11t |
| Gross Profit | ₩2.10t |
| Other Expenses | ₩1.07t |
| Earnings | ₩1.03t |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.45k |
| Gross Margin | 49.91% |
| Net Profit Margin | 24.42% |
| Debt/Equity Ratio | 14.2% |
How did A207940 perform over the long term?
See historical performance and comparison